title: Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans.
abstract: High titers of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection are directed primarily against the third hypervariable domain (V3) of the virion envelope glycoprotein gp120. This region has been designated the principal neutralizing domain of HIV-1. Because the frequency and significance of autologous V3 antibodies in natural infection are not fully clarified, we have cloned, sequenced, and expressed the V3 domain from virus of HIV-1-infected patients to test the autologous and heterologous V3 antibody response. The resulting recombinant Escherichia coli V3 fusion proteins reacted strongly with both autologous and heterologous patient antibodies in Western blots. Thirty-one different V3 fragments were cloned from 24 hemophiliac patients with different immunological and clinical statuses. Antibody reactivity against the autologous V3 fusion proteins was detected in all serum samples except one; moreover, all serum samples contained antibody reactivity against a vast majority of heterologous fusion proteins despite significant amino acid variability in V3. The results suggest that V3 antibodies are highly prevalent; further, we find no association between the stage of the HIV-1 infection and the presence of V3 antibodies.
authors.affiliation: Department of Virology, State Serum Institute, Copenhagen, Denmark.
authors.forename: K
authors.initials: K
authors.lastname: Holmbäck
authors.forename: P
authors.initials: P
authors.lastname: Kusk
authors.forename: E F
authors.initials: EF
authors.lastname: Hulgaard
authors.forename: T H
authors.initials: TH
authors.lastname: Bugge
authors.forename: E
authors.initials: E
authors.lastname: Scheibel
authors.forename: B O
authors.initials: BO
authors.lastname: Lindhardt
mesh_terms: D000595:Amino Acid Sequence; D000910:Antibodies, Heterophile; D001483:Base Sequence; D003001:Cloning, Molecular; D003429:Cross Reactions; D014644:Genetic Variation; D015483:HIV Antibodies / Q000097:blood*; D015699:HIV Envelope Protein gp120 / Q000096:biosynthesis / Q000276:immunology* / Q000302:isolation & purification; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology / Q000302:isolation & purification; D016415:Sequence Alignment; D017422:Sequence Analysis, DNA
chemical_list: D000910:Antibodies, Heterophile; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D009838:Oligodeoxyribonucleotides; D011994:Recombinant Proteins